消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗

2023-09-30 国外肿瘤科相关专家小组（统称） Front Oncol 发表于上海

胆管癌

目前，全身治疗治疗的领域正在扩大，本文主要针对局部晚期或转移性胆管癌患者的全身治疗提供共识指导。

中文标题：

2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗

英文标题：

Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma - an Austrian expert consensus statement

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2023-09-30

简要介绍：

局部晚期或转移性胆管癌是一种预后差的侵袭性癌症。对于局部晚期或转移性胆管癌的一线治疗，顺铂/吉西他滨已作为标准治疗方案超过10年。目前，全身治疗治疗的领域正在扩大，本文主要针对局部晚期或转移性胆管癌患者的全身治疗提供共识指导。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=fafd51c0033a11bc, title=2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗, enTitle=Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma - an Austrian expert consensus statement, guiderFrom= Front Oncol, authorId=0, author=, summary=目前，全身治疗治疗的领域正在扩大，本文主要针对局部晚期或转移性胆管癌患者的全身治疗提供共识指导。, cover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Sat Sep 30 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<div class="guideDetailsCont flex-row-between-start" style="color: #333333;"> <div class="detailsContRight" style="color: #222222;"> <p>局部晚期或转移性胆管癌是一种预后差的侵袭性癌症。对于局部晚期或转移性胆管癌的一线治疗，顺铂/吉西他滨已作为标准治疗方案超过10年。目前，全身治疗治疗的领域正在扩大，本文主要针对局部晚期或转移性胆管癌患者的全身治疗提供共识指导。</p> </div> </div> <div class="detailsQRWrapper" style="color: #333333;"> <div id="app_detail" class="detailsQR" title="https://m.medlive.cn/guide/1/29820">&nbsp;</div> </div>, tagList=[TagDto(tagId=2872, tagName=胆管癌)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=2872, articleKeyword=胆管癌, articleKeywordNum=6, guiderKeywordId=2872, guiderKeyword=胆管癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3952, appHits=17, showAppHits=0, pcHits=290, showPcHits=3932, likes=1, shares=4, comments=4, approvalStatus=1, publishedTime=Mon Sep 18 14:50:00 CST 2023, publishedTimeString=2023-09-30, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=6, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Sep 18 12:12:40 CST 2023, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Fri Jan 05 01:03:49 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗.pdf)])
2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2172927, encodeId=d70d21e2927ff, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea21985113, createdName=在风中, createdTime=Mon Dec 04 21:16:18 CST 2023, time=2023-12-04, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2165886, encodeId=961721658861a, content=认真学习，收获满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af092093304, createdName=yixueyuan, createdTime=Tue Oct 31 13:32:44 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165859, encodeId=99af216585927, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/23/914ab8c212b86139546fc16eed98b36f.jpg, createdBy=90821711402, createdName=1dea4a7em68(暂无匿称), createdTime=Tue Oct 31 10:36:05 CST 2023, time=2023-10-31, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2158304, encodeId=882d2158304a5, content=认真学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/52b37e2b3500d64012322279de0ea155/6701adcc53b818352061ec3cb03e7922.jpg, createdBy=5f871554375, createdName=54414749, createdTime=Mon Sep 18 15:57:15 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省)]
    2023-12-04 在风中 来自甘肃省

    值得学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2172927, encodeId=d70d21e2927ff, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea21985113, createdName=在风中, createdTime=Mon Dec 04 21:16:18 CST 2023, time=2023-12-04, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2165886, encodeId=961721658861a, content=认真学习，收获满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af092093304, createdName=yixueyuan, createdTime=Tue Oct 31 13:32:44 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165859, encodeId=99af216585927, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/23/914ab8c212b86139546fc16eed98b36f.jpg, createdBy=90821711402, createdName=1dea4a7em68(暂无匿称), createdTime=Tue Oct 31 10:36:05 CST 2023, time=2023-10-31, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2158304, encodeId=882d2158304a5, content=认真学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/52b37e2b3500d64012322279de0ea155/6701adcc53b818352061ec3cb03e7922.jpg, createdBy=5f871554375, createdName=54414749, createdTime=Mon Sep 18 15:57:15 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省)]
    2023-10-31 yixueyuan 来自江苏省

    认真学习，收获满满

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2172927, encodeId=d70d21e2927ff, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea21985113, createdName=在风中, createdTime=Mon Dec 04 21:16:18 CST 2023, time=2023-12-04, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2165886, encodeId=961721658861a, content=认真学习，收获满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af092093304, createdName=yixueyuan, createdTime=Tue Oct 31 13:32:44 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165859, encodeId=99af216585927, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/23/914ab8c212b86139546fc16eed98b36f.jpg, createdBy=90821711402, createdName=1dea4a7em68(暂无匿称), createdTime=Tue Oct 31 10:36:05 CST 2023, time=2023-10-31, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2158304, encodeId=882d2158304a5, content=认真学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/52b37e2b3500d64012322279de0ea155/6701adcc53b818352061ec3cb03e7922.jpg, createdBy=5f871554375, createdName=54414749, createdTime=Mon Sep 18 15:57:15 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省)]
    2023-10-31 1dea4a7em68(暂无匿称) 来自福建省

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2172927, encodeId=d70d21e2927ff, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea21985113, createdName=在风中, createdTime=Mon Dec 04 21:16:18 CST 2023, time=2023-12-04, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2165886, encodeId=961721658861a, content=认真学习，收获满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af092093304, createdName=yixueyuan, createdTime=Tue Oct 31 13:32:44 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165859, encodeId=99af216585927, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/23/914ab8c212b86139546fc16eed98b36f.jpg, createdBy=90821711402, createdName=1dea4a7em68(暂无匿称), createdTime=Tue Oct 31 10:36:05 CST 2023, time=2023-10-31, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2158304, encodeId=882d2158304a5, content=认真学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/52b37e2b3500d64012322279de0ea155/6701adcc53b818352061ec3cb03e7922.jpg, createdBy=5f871554375, createdName=54414749, createdTime=Mon Sep 18 15:57:15 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省)]
    2023-09-18 54414749 来自湖北省

    认真学习!

    0

相关指南

2022 AASLD实践指南：原发性硬化性胆管炎和胆管癌

美国肝病研究学会(AASLD,American Association for the Study of Liver Diseases) · 2023-02-02

胆管癌光动力治疗临床应用技术规范专家共识

中国医师协会外科医师分会胆道外科医师委员会 · 2023-03-27

胆管癌患者光动力治疗避光管理的最佳证据总结

广州医科大学附属第二医院肝胆外科一区 · 2022-12-10

2022 ESMO临床实践指南：胆管癌的诊断，治疗以及随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2022-11-03

2020 意大利临床实践指南：胆管癌-第1部分：分类，诊断和分期

意大利肝病学会(AISF,Italian Association for the Study of the Liver) · 2020-09-03

2016 ESMO临床诊疗指南：胆管癌的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2016-09-20

拓展阅读

Genes & Diseases：Mariko Murata教授团队发现葡萄糖转运蛋白5在人胆管癌细胞中调控果糖代谢

研究分析了GLUT5在人胆管癌细胞和组织中的表达，评估了GLUT5的敲低对肿瘤抑制的效果，并探讨了GLUT5介导的胆管癌细胞增殖机制。

European Radiology:基于MR特征的肝内肿块型胆管癌与单发结直肠肝转移的简便评分系统

肝脏磁共振成像 (MRI) 广泛应用于临床研究IMCC和CRLM。先前的研究试图明确MRI特征来区分IMCC和肝转移。

【热点解读】2023 法国国家临床实践指南：胆道癌的诊断，治疗以及随访

胆道癌（BTCs）比较少见，主要包括胆囊癌、胆管癌（CCA）和壶腹腺癌。本文主要总结了法国胆道癌管理指南，主要内容涉及胆道癌的诊断和治疗。

Gut：山东大学徐云飞/张宗利等合作发现肥大细胞通过胆管癌-胆汁相互作用模式促进胆管癌进展

该研究揭示了胆管癌微环境中肥大细胞与胆管癌功能的相互作用。

新药Lirafugratinib治疗FGFR突变实体瘤疗效显著，对胆管癌高达82.4%客观缓解率！

这些数据表明，RLY-4008在FGFR2融合型胆管癌患者以及其他多种FGFR2改变型肿瘤患者中具有显著的抗肿瘤疗效。

真实数据，高达50%的胆管癌是分子靶向治疗的潜在受益者，有机会活得更好、更长！

今天我们通过最近的一篇文献，来给大家系统梳理胆管癌这个类型的肿瘤，以希望彻底回答胆管癌是否需要做基因检测这个问题。

2015 胆管癌诊断与治疗——外科专家共识

中华医学会外科学分会 · 2015-01-15

肝门部胆管癌规范化诊治专家共识（2015）

中国抗癌协会(Chinese Anti-cancer Association) · 2015-08-30

肝门部胆管癌诊断和治疗指南（2013版）的解读与思考

暂未更新 · 2016-06-08

AHPBA专家共识声明：肝内胆管癌（2015年）

美国肝胰胆协会(AHPBA,American Hepato-Pancreato-Biliary Association) · 2016-06-08

2016 ESMO临床诊疗指南：胆管癌的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2016-09-20

2020 意大利临床实践指南：胆管癌-第1部分：分类，诊断和分期

意大利肝病学会(AISF,Italian Association for the Study of the Liver) · 2020-09-03